Search
lanifibranor
Indications:
- non-alcoholic steatohepatitis
Dosage:
- 1200 mg PO QD
Adverse effects:
- diarrhea, nausea
- peripheral edema
- anemia
- weight gain
Mechanism of action:
- pan-PPAR agonist
- attenuates progression of fibrosis in non-alcoholic steatohepatitis
General
gastrointestinal agent
peroxisome proliferator; PPAR agonist; PPAR gamma agonist
Database Correlations
PUBCHEM cid=68677842
References
- Francque SM, Bedossa P, Ratziu V et al.
A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH.
N Engl J Med 2021 Oct 21; 385:1547.
PMID: 34670042
https://www.nejm.org/doi/10.1056/NEJMoa2036205